nach oben

European Radiology

Erschienen in:

22.07.2019 | Magnetic Resonance

Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study

verfasst von: Liran Domachevsky, Hanna Bernstine, Natalia Goldberg, Meital Nidam, Onofrio A. Catalano, David Groshar

Erschienen in: European Radiology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Despite the advantages of prostate-specific membrane antigen (PSMA)-PET/MR over PSMA-PET/CT, its relatively long scanning time and suboptimal PET attenuation correction necessitate careful assessment of the most appropriate setting for this type of study. We assessed lesion agreement between PSMA-PET/MR and PSMA-PET/CT in patients undergoing initial evaluation of prostate cancer.

Methods

This was a prospective study of consecutive patients with histological biopsy-proven prostate cancer who underwent pelvic PSMA-PET/MR followed by whole-body PSMA-PET/CT. All conspicuous PSMA-avid foci were counted on PSMA-PET/CT and PSMA-PET/MR with CT or MR correlation. Analysis was performed for intra-prostatic lesions, capsular invasion, seminal vesicle involvement and lymph node and bone involvement. Incidental and significant findings seen on PSMA-PET/CT outside the PSMA-PET/MR field of view were also analysed. Agreements between PSMA-PET/CT and PSMA-PET/MR findings were performed using Cohen’s kappa test.

Results

Image analysis was performed on 140 patients (mean age, 67.3 ± 8.2 years). Agreement between PSMA PET/CT and PSMA-PET/MR was very good for intra-prostatic PSMA-avid foci (K = 0.85) and pelvic lymph nodes (K = 0.98), good for PSMA-avid bone metastases (K = 0.76) and fair for prostatic capsular invasion (K = 0.25) and seminal vesicle involvement (K = 0.31). Twelve patients (8.5%) had incidental findings and two patients (1.4%) had clinically significant findings.

Conclusion

Limited pelvic PSMA-PET/MR has very good agreement with PET/CT regarding PSMA-avid prostatic, regional lymph nodes and bone lesions, and is superior to PET/CT with regard to capsular invasion and seminal vesicle involvement.

Key Points

• Limited pelvic PSMA-PET/MR is superior to whole-body PSMA-PET/CT in detecting extensions of localised disease, mainly due to the high soft tissue resolution of MR.

• Limited pelvic PSMA-PET/MR may be useful for initial evaluation of histological biopsy-proven prostate cancer.

• Further studies are warranted to evaluate limited pelvic PSMA-PET/MR for screening and active surveillance in selected populations.

Rauscher I, Maurer T, Beer AJ et al (2016) Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med 57(11):1713–1719CrossRef

Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668–674CrossRef

Schwarzenboeck SM, Rauscher I, Bluemel C et al (2017) PSMA ligands for PET imaging of prostate cancer. J Nucl Med 58(10):1545–1552CrossRef

Maurer T, Gschwend JE, Rauscher I et al (2016) Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436–1443CrossRef

Pyka T, Okamoto S, Dahlbender M et al (2016) Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43(12):2114–2121CrossRef

Giesel FL, Sterzing F, Schlemmer HP et al (2016) Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 43(8):1400–1406CrossRef

Berger I, Annabattula C, Lewis J et al (2018) (68)Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 21(2):204–211CrossRef

Park SY, Zacharias C, Harrison C et al (2018) Gallium 68 PSMA-11 PET/mr imaging in patients with intermediate- or high-risk prostate cancer. Radiology. 288(2):495–505CrossRef

Eiber M, Weirich G, Holzapfel K et al (2016) Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70(5):829–836CrossRef

10.

Al-Bayati M, Grueneisen J, Lütje S et al (2018) Integrated 68gallium labelled prostate-specific membrane antigen-11 positron emission tomography/magnetic resonance imaging enhances discriminatory power of multi-parametric prostate magnetic resonance imaging. Urol Int 100(2):164–171CrossRef

11.

Domachevsky L, Goldberg N, Bernstine H, Nidam M, Groshar D (2018) Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11. Eur Radiol 28(12):5275–5283CrossRef

12.

Öbek C, Doğanca T, Demirci E et al (2017) The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging 44(11):1806–1812CrossRef

13.

Freitag MT, Radtke JP, Hadaschik BA et al (2016) Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 43(1):70–83CrossRef

14.

Domachevsky L, Bernstine H, Goldberg N et al (2017) Early (68)GA-PSMA PET/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET/CT. Clin Radiol 72(11):944–950CrossRef

15.

Thalgott M, Düwel C, Rauscher I et al (2018) One-stop shop whole-body (68)Ga-PSMA-11 PET/MRI compared to clinical nomograms for preoperative T- and N-staging of high-risk prostate cancer. J Nucl Med 59(12):1850–1856CrossRef

16.

Verburg FA, Pfestroff A (2016) Imaging: PSMA PET-CT in initial prostate cancer staging. Nat Rev Urol 13(9):498–499CrossRef

17.

Zhang Q, Zang S, Zhang C et al (2017) Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. J Transl Med 15(1):230CrossRef

18.

Afshar-Oromieh A, Haberkorn U, Schlemmer HP et al (2014) Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41(5):887–897CrossRef

19.

Kabasakal L, Demirci E, Ocak M et al (2015) Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 36(6):582–587CrossRef

20.

Perveen G, Arora G, Damle NA et al (2018) Role of early dynamic positron emission tomography/computed tomography with 68Ga-prostate-specific membrane antigen-HBED-CC in patients with adenocarcinoma prostate: initial results. Indian J Nucl Med 33(2):112–117CrossRef

21.

Uprimny C, Kroiss AS, Decristoforo C et al (2017) Early dynamic imaging in (68)Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging 44(5):765–775CrossRef

22.

Hofman MS, Iravani A, Nzenza T, Murphy DG (2018) Advances in urologic imaging: prostate-specific membrane antigen ligand PET imaging. Urol Clin North Am 45(3):503–524CrossRef

23.

Fendler WP, Schmidt DF, Wenter V et al (2016) 68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer. J Nucl Med 57(11):1720–1725CrossRef

24.

Muehlematter UJ, Rupp NJ, Mueller J, Eberli D, Burger IA (2018) 68Ga-PSMA PET/MR-positive, histopathology-proven prostate cancer in a patient with negative multiparametric prostate MRI. Clin Nucl Med 43(8):e282–e2e4CrossRef

25.

Beheshti M, Paymani Z, Brilhante J et al (2018) Optimal time-point for (68)Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation? Eur J Nucl Med Mol Imaging 45(7):1188–1196CrossRef

Titel: Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study
verfasst von: Liran Domachevsky
Hanna Bernstine
Natalia Goldberg
Meital Nidam
Onofrio A. Catalano
David Groshar
Publikationsdatum: 22.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 1/2020
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-019-06353-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study